Recently, ICIs such as anti-programmed cell death protein 1 (PD-1) antibodies, anti- programmed cell death ligand 1 (PD-L1) antibodies, and anti-CTLA-4 antibodies have contributed greatly to cancer therapy and have improved the prognosis of advanced cancer patients. This evidence concerns the gene PDCD1 and cancer.